Af­ter year­long de­lay, FDA com­pletes in­spec­tion for No­var­tis, BeiGene's an­ti-PD-1 drug from Chi­na

The FDA has com­plet­ed its man­u­fac­tur­ing in­spec­tion for tislelizum­ab and the ap­pli­ca­tion is mov­ing for­ward, No­var­tis’ part­ner BeiGene an­nounced Tues­day morn­ing at its R&D day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER